Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?

​Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Best Growth Stocks to Buy With Highest Upside Potential. Wall Street has a positive view on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as 71% of the 28 analysts covering the stock have a Buy rating. Moreover, the 12-month median price target of the Street reflects more than 36.9% upside from the current level.

​On April 1, Barclays analyst Eliana Merle maintained a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with a price target of $527. The rating comes after the company presented clinical data on its cardiovascular portfolio at the American College of Cardiology’s Annual Scientific Session. At the conference, the company shared HELIOS-B study results for Vutrisiran, its ATTR-CM therapy.

​Management noted that analyses covered quality-of-life gains, subgroup efficacy, and real-world adherence over 613.8 days, where 93.8% of patients stayed on treatment. In a post hoc analysis, 8.0% of Vutrisiran patients progressed to advanced disease versus 10.7% on placebo during the double-blind phase.

​That said, the company posted strong gains in fiscal Q4 2025 results. It posted a revenue of $1.10 billion, up 84.95% year-over-year. The EPS for the quarter came in at $0.82.

​Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biopharmaceutical company that develops and commercializes novel therapeutics based on ribonucleic acid interference.

While we acknowledge the risk and potential of ALNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Hot Growth Stocks to Invest in Right Now and 7 Ridiculously Cheap Stocks to Buy According to Wall Street Analysts. 

Disclosure: None. Follow Insider Monkey on Google News.